Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huayan Xu

Showing results (91-100 of 92) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 92 results.
Frontiers in Oncology|June 7, 2021
Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-<i>Ad hoc</i> Analyses of Pooled Data From Two Clinical TrialsXue Bai, Jie Dai, Caili Li, et al.
JAMA Oncology|June 1, 2023
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical TrialLili Mao, Bin Lian, Caili Li, et al.
Pageof 10

Showing results (91-100 of 92) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 92 results.
Frontiers in Oncology|June 7, 2021
Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-<i>Ad hoc</i> Analyses of Pooled Data From Two Clinical TrialsXue Bai, Jie Dai, Caili Li, et al.
JAMA Oncology|June 1, 2023
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical TrialLili Mao, Bin Lian, Caili Li, et al.
Pageof 10